• Home
  • Health A To Z
  • Drugs A To Z
  • Cancer A to Z
  • Write For Us
  •   
HealthInfi




  • Cancer A to Z
  • Drugs A To Z

What Is Herceptin? (Trastuzumab)

Posted on November 27, 2017
healthinfi.png.303m

Herceptin is the brand name of a medicine called trastuzumab. It’s used to treat some types of breast cancer, oesophageal cancer and stomach cancer. Herceptin (chemical name: trastuzumab) can be an effective treatment both before and after surgery for people with HER2-positive breast cancer. It has also been shown to reduce the risk of breast cancer recurrence after initial surgery.

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes.

If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication.  Trastuzumab is given by slow injection into a vein and injection just under the skin.

Common side effects include fever, infection, cough, headache, trouble sleeping, and rash.Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication

 

Trastuzumab was approved for medical use in the United States in 1998.It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.The wholesale price in the developing world is between 1,800 and 1,955 USD per 440 mg vial.In the United Kingdom a 150 mg vial costs the NHS 407.00 pounds.

 Herceptin can be used in several different ways

  • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC→TH“
  • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH“
  • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin)-based therapy (a type of chemotherapy)

*High risk is defined as ER/PR-positive with one of the following features: tumor size greater than 2 cm, age less than 35 years, or tumor Grade 2 or 3.

Indications

Adjuvant Breast Cancer

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.

Herceptin can be used in several different ways:

  • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC→TH”
  • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH”
  • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)

Patients are selected for therapy based on an FDA-approved test for Herceptin

Adjuvant Breast Cancer

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.

Herceptin can be used in several different ways:

  • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC→TH“
  • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH“
  • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)

Patients are selected for therapy based on an FDA-approved test for Herceptin

Metastatic Breast Cancer

Herceptin has 2 approved uses in metastatic breast cancer:

  • Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
  • Herceptin alone is approved for the treatment of HER2+ breast cancer in patients who have received one or more chemotherapy courses for metastatic disease

Gastric Cancer

Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.

When Herceptin is used

Herceptin can be used to treat:

  • early HER2 positive breast cancer, following surgery and/or radiotherapy and chemotherapy, to reduce the risk of the cancer coming back
  • advanced HER2 positive breast cancer that has spread from the breast (metastatic breast cancer), to slow the growth of the cancer and increase survival time
  • advanced HER2 positive stomach cancer that has spread out of the stomach (metastatic stomach cancer)
  • advanced HER2 positive gastro-oesophageal cancer, affecting the area where the oesophagus (food pipe) meets the stomach

If you have breast, oesophageal or stomach cancer, tests will be carried out to check if your cancer is HER2 positive before Herceptin is offered.

What This Drug Is Used For:

  • Trastuzumab is used to treat metastatic (spread) breast cancer.  It is effective against tumors that overexpress the HER2/neu protein.
  • As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu protein positive breast cancer.
  • Treatment of gastric (stomach) cancer
  • It is not known whether or not trastuzumab may be effective in other cancers that may also have this HER-2/neu protein, including ovarian, colon, endometrial, lung, bladder, prostate, and salivary gland tumors.

How it works

Herceptin can help control the growth of cancer cells that contain high amounts of HER2 (human epidermal growth factor receptor 2).

HER2 is found in all human cells. It controls cell growth and repair.

But high levels of HER2 are found in some types of breast, oesophageal and stomach cancer, which helps the cancer cells grow and survive.

These are known as HER2 positive cancers. About one in five breast and stomach cancers are HER2 positive.

Herceptin works by blocking the effects of HER2 and encouraging the immune system (the body’s natural defences) to attack and kill the cancer cells.

It is a type of targeted treatment.

It is used for cancers that have large amounts of a protein called HER2 (human epidermal growth factor receptor 2).

Some breast cancers and stomach cancers have large amounts of HER2 and they are called HER2 positive cancers. HER2 makes the cancer cells grow and divide. When Herceptin attaches to HER2 it can make the cells stop growing and die.

Doctors use trastuzumab to treat some types of:

  • early breast cancer in adults
  • advanced breast cancer in adults
  • advanced stomach cancer in adults

Side Effects

HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following:

Heart Problems

These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN.

Infusion Reactions including:

  • Fever and chills
  • Feeling sick to your stomach (nausea)
  • Throwing up (vomiting)
  • Pain (in some cases at tumor sites)
  • Headache
  • Dizziness
  • Shortness of breath

Herceptin often causes side effects, although many of these will become less severe over time.

Some patients receiving HERCEPTIN for breast cancer had the following side effects:

  • Fever
  • Feeling sick to your stomach (nausea)
  • Throwing up (vomiting)
  • Infusion reactions
  • Diarrhea
  • Infections
  • Increased cough
  • Headache
  • Feeling tired
  • Shortness of breath
  • Rash
  • Low white and red blood cell counts
  • Muscle pain

Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects:

  • Low white blood cell counts
  • Diarrhea
  • Feeling tired
  • Low red blood cell counts
  • Swelling of the mouth lining
  • Weight loss
  • Upper respiratory tract infections
  • Fever
  • Low platelet counts
  • Swelling of the mucous membranes
  • Swelling of the nose and throat
  • Change in taste

Interactions

Patients who receive anthracycline after stopping Herceptin may be at increased risk of cardiac dysfunction because of trastuzumab’s long washout period based on population PK analysis . If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Herceptin. If anthracyclines are used, the patient’s cardiac function should be monitored carefully.

Precautions

Cardiomyopathy

Herceptin can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death.Herceptin can also cause asymptomatic decline in left ventricular ejection fraction (LVEF).

There is a 4−6 fold increase in the incidence of symptomatic myocardial dysfunction among patients receiving Herceptin as a single agent or in combination therapy compared with those not receiving Herceptin. The highest absolute incidence occurs when Herceptin is administered with an anthracycline.

Withhold Herceptin for ≥ 16% absolute decrease in LVEF from pre-treatment values or an LVEF value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values . The safety of continuation or resumption of Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been studied.

Patients who receive anthracycline after stopping Herceptin may also be at increased risk of cardiac dysfunction

Cardiac Monitoring

Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.

The following schedule is recommended:

  • Baseline LVEF measurement immediately prior to initiation of Herceptin
  • LVEF measurements every 3 months during and upon completion of Herceptin
  • Repeat LVEF measurement at 4 week intervals if Herceptin is withheld for significant left ventricular cardiac dysfunction.
  • LVEF measurements every 6 months for at least 2 years following completion of Herceptin as a component of adjuvant therapy.

In Study 1, 15% (158/1031) of patients discontinued Herceptin due to clinical evidence of myocardial dysfunction or significant decline in LVEF after a median follow-up duration of 8.7 years in the AC-TH arm. In Study 3 (one-year Herceptin treatment), the number of patients who discontinued Herceptin due to cardiac toxicity at 12.6 months median duration of follow-up was2.6% (44/1678).

 In Study 4, a total of 2.9% (31/1056) of patients in the TCH arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued Herceptin due to cardiac toxicity.

Among 64 patients receiving adjuvant chemotherapy (Studies 1 and 2) who developed congestive heart failure, one patient died of cardiomyopathy, one patient died suddenly without documented etiology, and 33 patients were receiving cardiac medication at last follow-up. Approximately 24% of the surviving patients had recovery to a normal LVEF (defined as ≥ 50%) and no symptoms on continuing medical management at the time of last follow-up. Incidence of congestive heart failure (CHF) is presented in Table 1. The safety of continuation or resumption of Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been studied.

Infusion Reactions

Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion included nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia. 

In post-marketing reports, serious and fatal infusion reactions have been reported. Severe reactions, which include bronchospasm, anaphylaxis, angioedema, hypoxia, and severe hypotension, were usually reported during or immediately following the initial infusion. However, the onset and clinical course were variable, including progressive worsening, initial improvement followed by clinical deterioration, or delayed post-infusion events with rapid clinical deterioration. For fatal events, death occurred within hours to days following a serious infusion reaction.

Interrupt Herceptin infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be strongly considered in all patients with severe infusion reactions.

There are no data regarding the most appropriate method of identification of patients who may safely be retreated with Herceptin after experiencing a severe infusion reaction. Prior to resumption of Herceptin infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. While some patients tolerated Herceptin infusions, others had recurrent severe infusion reactions despite pre-medications.

Embryo-Fetal Toxicity

Herceptin can cause fetal harm when administered to a pregnant woman. In post-marketing reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.

Verify the pregnancy status of females of reproductive potential prior to the initiation of Herceptin. Advise pregnant women and females of reproductive potential that exposure to Herceptin during pregnancy or within 7 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of Herceptin.

Pulmonary Toxicity

Herceptin use can result in serious and fatal pulmonary toxicity. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity.

Exacerbation Of Chemotherapy-Induced Neutropenia

In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3−4 neutropenia and of febrile neutropenia were higher in patients receiving Herceptin in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received Herceptin and those who did not.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Herceptin has not been tested for carcinogenic potential.

No evidence of mutagenic activity was observed when trastuzumab was tested in the standard Ames bacterial and human peripheral blood lymphocyte mutagenicity assays at concentrations of up to 5000 mcg/mL. In an in vivo micronucleus assay, no evidence of chromosomal damage to mouse bone marrow cells was observed following bolus intravenous doses of up to 118 mg/kg of trastuzumab.

A fertility study was conducted in female Cynomolgus monkeys at doses up to 25 times the weekly recommended human dose of 2 mg/kg of trastuzumab and has revealed no evidence of impaired fertility, as measured by menstrual cycle duration and female sex hormone levels.

Use In Specific Populations

Pregnancy

Pregnancy Exposure Registry And Pharmacovigilance Program

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Herceptin during pregnancy.

In addition, there is a pregnancy pharmacovigilance program for Herceptin. If Herceptin is administered during pregnancy, or if a patient becomes pregnant while receiving Herceptin or within 7 months following the last dose of Herceptin,

Risk Summary

Herceptin can cause fetal harm when administered to a pregnant woman. In post-marketing reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios and of oligohydramnios sequence, manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Apprise the patient of the potential risks to a fetus. There are clinical considerations if Herceptin is used in a pregnant woman or if a patient becomes pregnant within 7 months following the last dose of Herceptin.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Monitor women who received Herceptin during pregnancy or within 7 months prior to conception for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.

Data

Human Data

In post-marketing reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios and of oligohydramnios sequence, manifesting in the fetus as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. These case reports described oligohydramnios in pregnant women who received Herceptin either alone or in combination with chemotherapy. In some case reports, amniotic fluid index increased after Herceptin was stopped. In one case, Herceptin therapy resumed after amniotic index improved and oligohydramnios recurred.

Animal Data

In studies where trastuzumab was administered to pregnant Cynomolgus monkeys during the period of organogenesis at doses up to 25 mg/kg given twice weekly (up to 25 times the recommended weekly human dose of 2 mg/kg), trastuzumab crossed the placental barrier during the early (Gestation Days 20 to 50) and late (Gestation Days 120 to 150) phases of gestation. The resulting concentrations of trastuzumab in fetal serum and amniotic fluid were approximately 33% and 25%, respectively, of those present in the maternal serum but were not associated with adverse developmental effects.

Lactation

Risk Summary

There is no information regarding the presence of trastuzumab in human milk, the effects on the breastfed infant, or the effects on milk production. Published data suggest human IgG is present in human milk but does not enter the neonatal and infant circulation in substantial amounts.

Trastuzumab was present in the milk of lactating Cynomolgus monkeys but not associated with neonatal toxicity Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Herceptin treatment and any potential adverse effects on the breastfed child from Herceptin or from the underlying maternal condition. This consideration should also take into account the trastuzumab wash out period of 7 months.

Data

In lactating Cynomolgus monkeys, trastuzumab was present in breast milk at about 0.3% of 614 maternal serum concentrations after pre-(beginning Gestation Day 120) and post-partum (through Post-partum Day 28) doses of 25 mg/kg administered twice weekly (25 times the recommended weekly human dose of 2 mg/kg of Herceptin). Infant monkeys with detectable serum levels of trastuzumab did not exhibit any adverse effects on growth or development from birth to 1 month of 618 age.

Females And Males Of Reproductive Potential

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to the initiation of Herceptin.

Contraception

Females

Herceptin can cause embryo-fetal harm when administered during pregnancy. Advise females of reproductive potential to use effective contraception during treatment with Herceptin and for 7 months following the last dose of Herceptin.

Pediatric Use

The safety and effectiveness of Herceptin in pediatric patients have not been established.

Geriatric Use

Herceptin has been administered to 386 patients who were 65 years of age or over (253 in the adjuvant treatment and 133 in metastatic breast cancer treatment settings). The risk of cardiac dysfunction was increased in geriatric patients as compared to younger patients in both those receiving treatment for metastatic disease in Studies 5 and 6, or adjuvant therapy in Studies 1 and 2.

Limitations in data collection and differences in study design of the 4 studies of Herceptin in adjuvant treatment of breast cancer preclude a determination of whether the toxicity profile of Herceptin in older patients is different from younger patients. The reported clinical experience is not adequate to determine whether the efficacy improvements (ORR, TTP, OS, DFS) of Herceptin treatment in older patients is different from that observed in patients < 65 years of age for metastatic disease and adjuvant treatment.

In Study 7 (metastatic gastric cancer), of the 294 patients treated with Herceptin, 108 (37%) were 65 years of age or older, while 13 (4.4%) were 75 and over.

No overall differences in safety or effectiveness were observed.

  • Before starting trastuzumab treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
  • Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment.  Pregnancy category B (there is no evidence of risk in humans based on negative animal studies.  Use in pregnancy only if clearly needed).
  • For both men and women: It is not recommended to conceive a child (get pregnant) while taking trastuzumab. Barrier methods of contraception, such as condoms, are recommended. Discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
  • Do not breast feed while taking this medication.

Treatment

The optimal duration of add-on trastuzumab is currently unknown. One year of treatment is generally accepted based on current clinical trial evidence that demonstrated the superiority of one-year treatment over none. However, a small Finnish trial also showed similar improvement with nine weeks of treatment over no therapy. Because of the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the currently accepted practice of treatment for one year.

Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive. Consequently, some countries with a taxpayer-funded public health system, such as New Zealand, chose to fund limited adjuvant therapy. However, subsequently New Zealand has revised its policy and now funds trastuzumab treatment for up to 12 months. Clinical trial data from Roche show that one year of therapy balances efficacy against adverse side effects.

For more information visit us our website: https://www.healthinfi.com

1 250
By HealthInfi
1 250
2b breast cancerabvd chemotherapyac chemotherapyadenocarcinomaadjuvant chemotherapyadjuvant herceptinado trastuzumabafter herceptin treatmentalcohol and herceptinanti her2anti her2 neuantibodiesantimicrobial agents and chemotherapyautoexploracionavastinbenignobest treatment for her2 positive breast cancerbevacizumabbevacizumab avastinbiological therapybiopsiablood cancerbreast cancerbreast cancer chemo drugsbreast cancer drugsbreast cancer drugs herceptinbreast cancer er positive her2 negativebreast cancer er pr her2breast cancer er pr positive her2 negativebreast cancer herbreast cancer her2 positive life expectancybreast cancer proteinbreast cancer receptorsBreast Cancer Treatmentbreast cancer treatment drugsbreast injectionsbuy herceptinbuy trastuzumabcampathcan her2 positive breast cancer be curedcan her2 positive breast cancer returncan herceptin be given without chemotherapyCancercancer chemotherapycancer de mamacancer drug herceptincancer her2cancer immunotherapycancer positivecancer treatmentcapecitabincapecitabinacapecitabinecapecitabine xelodacarcinomacauses of her2 positive breast cancercerb2cerb2 negativecervixcetuximabchances of her2 breast cancer returningchemo for her2 positive breast cancerchemotherapychemotherapy drugschemotherapy for breast cancerchemotherapy for her2 positive breast cancerchemotherapy hair losschemotherapy side effectschemotherapy treatmentchemotherapy typescost of herceptin injection in indiacost of herceptin per dosecost of herceptin treatmentcost of perjetacriocirugiacrohncytotoxic chemotherapydefine herceptindendritic cellsdocetaxeldocetaxel carboplatin trastuzumabdocetaxel herceptindocetaxel herceptin pertuzumabdocetaxel trastuzumabdoes her2 breast cancer recurdoes herceptin cause fatiguedoes herceptin cause hair lossdoes herceptin cause neuropathydoes herceptin cause weight gaindoes herceptin make you tireddoes herceptin workdrugs for her2 positive breast cancerearly stage her2 positive breast cancereffects of chemotherapyeloxatineemtansineer breast cancerer negative pr negative her2 positiveer positive and her2 negativeer positive her2 negativeer positive her2 positiveer positive her2 positive breast cancerer positive pr positive her2 negativeer positive pr positive her2 negative breast cancer treatmenter positive pr positive her2 positiveer pr her2er pr her2 positiveer pr negative breast cancer treatmenter pr positive breast cancerer pr positive her2 negativeer pr positive her2 negative treatmenter pr positive her2 positiveerb2erbberbb2erbb2 breast cancererbb2 positive breast cancererbituxestrogen positive her2 negative breast cancerestrogen progesterone positive her2 negativefda herceptinfibroadenomafish for her2 neu in breast cancerfolfox chemotherapygemcitabinegemtuzumabgenentech breast cancer drugsgrade 3 her2 positive breast cancerh2 breast cancerh2 cancerhalf life of herceptinhematopoiesisher 2 0her 2 neu positive survival ratesher 2 nuher breast cancerher cancerher gene breast cancerher ii breast cancerher negative breast cancerher positive breast cancerher positive breast cancer prognosisher positive cancerher receptor breast cancerher two positive breast cancerher1 and her2her1 breast cancerher1 her2her1 positive breast cancerher2her2 0her2 1 negativeher2 amplificationher2 and breast cancerher2 and cancerher2 and er positive breast cancerher2 and herceptinher2 blockerher2 borderlineher2 breasther2 breast cancerher2 breast cancer hereditaryher2 breast cancer life expectancyher2 breast cancer prognosisher2 breast cancer prognosis survival rateher2 breast cancer recurrenceher2 breast cancer stage 4 prognosisher2 breast cancer survivalher2 breast cancer survival rateher2 breast cancer survival rates 2013her2 breast cancer survivorsher2 breast cancer symptomsher2 breast cancer treatmenther2 cancerher2 cancer prognosisher2 cancer recurrenceher2 cancer survival rateher2 cancer treatmenther2 cellsher2 chemoher2 chemotherapyher2 drugsher2 equivocalher2 expressionher2 expression in breast cancerher2 fish negativeher2 fish positiveher2 fish testher2 geneher2 gene amplificationher2 gene breast cancerher2 gene hereditaryher2 genetic testingher2 herceptinher2 hormoneher2 markerher2 medicationher2 metastasisher2 metastatic breast cancerher2 metastatic breast cancer life expectancyher2 metastatic breast cancer survival ratesher2 negativeher2 negative breast cancerher2 negative breast cancer prognosisher2 negative breast cancer survival rateher2 negative breast cancer treatmenther2 negative breast cancer treatment optionsher2 negative cancerher2 negative estrogen positiveher2 negative metastatic breast cancerher2 negative prognosisher2 negative survival rateher2 negative treatmenther2 negative treatment optionsher2 neuher2 neu breast cancerher2 neu breast cancer prognosisher2 neu cancerher2 neu fishher2 neu geneher2 neu negativeher2 neu negative breast cancerher2 neu overexpressionher2 neu positiveher2 neu positive breast cancerher2 neu positive prognosisher2 neu positive treatmenther2 neu proteinher2 neu receptorher2 neu treatmenther2 normalher2 oncogeneher2 overexpressing breast cancerher2 overexpressionher2 positiveher2 positive breasther2 positive breast cancerher2 positive breast cancer diether2 positive breast cancer geneticher2 positive breast cancer prognosisher2 positive breast cancer prognosis 2014her2 positive breast cancer prognosis stage 1her2 positive breast cancer prognosis stage 4her2 positive breast cancer recurrenceher2 positive breast cancer recurrence ratesher2 positive breast cancer survivalher2 positive breast cancer survival rateher2 positive breast cancer survival rates 2011her2 positive breast cancer survival rates 2013her2 positive breast cancer survival rates 2014her2 positive breast cancer survivor storiesher2 positive breast cancer treatmenther2 positive breast cancer treatment guidelinesher2 positive breast cancer treatment optionsher2 positive cancerher2 positive cancer survival rateher2 positive cancer treatmenther2 positive diseaseher2 positive drugsher2 positive geneticher2 positive grade 3her2 positive grade 3 prognosisher2 positive herceptinher2 positive lung cancerher2 positive metastatic breast cancerher2 positive metastatic breast cancer prognosisher2 positive metastatic breast cancer survival rateher2 positive prognosisher2 positive recurrenceher2 positive recurrence rateher2 positive survival rateher2 positive survival rate 2014her2 positive treatmenther2 positive treatment optionsher2 positive tumorsher2 prognosisher2 prognosis with herceptinher2 proteinher2 protein breast cancerher2 protein overexpressionher2 receptorher2 receptor breast cancerher2 receptor negativeher2 receptor positiveher2 recurrenceher2 recurrence rateher2 resultsher2 scoreher2 stage 2 breast cancerher2 stands forher2 survivalher2 survival rate with herceptinher2 survival ratesher2 test resultsher2 testingher2 testing breast cancerher2 therapyher2 trastuzumabher2 treatmenther2 treatment optionsher2 triple positiveher2 triple positive breast cancerher2 tumorher2 tumor markerher2neuher2neu testher2newher2nuher2nueher3 breast cancerher3 positive breast cancerherceptestherceptinherceptin 150 mg priceherceptin 2herceptin 2 positive breast cancerherceptin 440herceptin 440 mgherceptin 440 mg priceherceptin 440 mg vialherceptin actionherceptin administrationherceptin adverse effectsherceptin adverse reactionsherceptin alcoholherceptin alone without chemoherceptin and alcoholherceptin and breast cancerherceptin and chemotherapyherceptin and diarrheaherceptin and hair lossherceptin and heartherceptin and heart damageherceptin and heart failureherceptin and heart problemsherceptin and lapatinibherceptin and perjetaherceptin and perjeta aloneherceptin and pregnancyherceptin and taxolherceptin and weight gainherceptin antibodyherceptin approvalherceptin approval dateherceptin australiaherceptin availability cost in indiaherceptin benefitsherceptin brand nameherceptin breast cancerherceptin breast cancer survivalherceptin breast cancer treatmentherceptin buyherceptin cancerherceptin cancer treatmentherceptin cardiac side effectsherceptin chemical structureherceptin chemoherceptin chemotherapyherceptin classificationherceptin clinical trialsherceptin colon cancerherceptin combination therapyherceptin companyherceptin contraindicationsherceptin costherceptin cost in indiaherceptin cost indiaherceptin cost per doseherceptin cost per dose in indiaherceptin cost per vialherceptin definitionherceptin diarrheaherceptin doseherceptin dose every 3 weeksherceptin dosing scheduleherceptin effectivenessherceptin efficacyherceptin eparherceptin every 3 weeksherceptin fdaherceptin fda approvalherceptin fda approval 1998herceptin fda labelherceptin for lifeherceptin formulationherceptin fundingherceptin gastric cancerherceptin gastric cancer fda approvalherceptin genentechherceptin genericherceptin hair growthherceptin hair lossherceptin half lifeherceptin heartherceptin heart damageherceptin heart failureherceptin heart problemsherceptin her2 negativeherceptin her2 positive breast cancerherceptin historyherceptin hormone therapyherceptin how it worksherceptin indicationsherceptin infusionherceptin infusion timeherceptin injectionherceptin injection costherceptin injection priceherceptin injection price in indiaherceptin ivherceptin j codeherceptin joint painherceptin labelherceptin lapatinibherceptin loading doseherceptin logoherceptin lung cancerherceptin manufacturerherceptin mechanismherceptin mechanism of actionherceptin medicareherceptin medicationherceptin metastatic breast cancerherceptin moaherceptin mode of actionherceptin molecular weightherceptin monoclonal antibodyherceptin monographherceptin muscle painherceptin negative breast cancerherceptin newsherceptin oralherceptin package insertherceptin perjetaherceptin perjeta taxotereherceptin piherceptin pill formherceptin positiveherceptin positive breast cancerherceptin positive breast cancer prognosisherceptin pregnancyherceptin prescribing informationherceptin priceherceptin price in usaherceptin price per doseherceptin product informationherceptin product monographherceptin rashherceptin receptorherceptin regimenherceptin rocheherceptin route of administrationherceptin side effectsherceptin side effects blogherceptin side effects forumherceptin side effects hair lossherceptin side effects heartherceptin side effects long termherceptin side effects nailsherceptin side effects neuropathyherceptin side effects skinherceptin side effects weight gainherceptin structureherceptin success rateherceptin survival ratesherceptin tabletsherceptin targetherceptin targeted therapyherceptin taxolherceptin taxotereherceptin testherceptin therapyherceptin toxicityherceptin treatmentherceptin treatment costherceptin treatment durationherceptin treatment regimenherceptin treatment scheduleherceptin treatment side effectsherceptin trialsherceptin ukherceptin usesherceptin vialherceptin vial sizeherceptin videoherceptin weight gainherceptin wikiherceptin wikipediaherceptin without chemoherceptiveherclon injectionhodgkinhormone positive breast cancerhormone receptor positive her2 negativehormone receptor positive metastatic breast cancerhow does herceptin affect the hearthow does herceptin workhow effective is herceptinhow effective is herceptin for breast cancerhow herceptin workshow is herceptin administeredhow is herceptin givenhow is herceptin madehow long can you take herceptinhow long does herceptin stay in the bodyhow long does herceptin stay in your bodyhow long does herceptin stay in your systemhow long does herceptin workhow long is herceptin givenhow much does herceptin costhow often is herceptin givenhr positive breast cancerhr positive her2 negativehr2 breast cancerhr2 breast cancer survival ratehr2 cancerhr2 negative breast cancerhr2 positivehr2 positive breast cancerhuman epidermal growth factor 2human epidermal growth factor receptor 2human epidermal growth factor receptor 2 her2immune cellsimmune systemimmunityimmunologyincidence of her2 positive breast cancerinduction chemotherapyinjection herceptininjection trastuzumab 10 mginmunoterapiainnate immunityintrathecal chemotherapyinvasive ductal carcinoma her2invasive ductal carcinoma her2 positiveinvasive ductal carcinoma her2 positive prognosisinventor of herceptinis her2 breast cancer curableis her2 breast cancer hereditaryis her2 geneticis her2 negative goodis her2 positive breast cancer curableis her2 positive breast cancer hereditaryis her2 positive geneticis herceptin a form of chemotherapyis herceptin a monoclonal antibodyis herceptin chemotherapyis herceptin considered chemotherapyiv herceptinkadcylalapatiniblapatinib and trastuzumablapatinib trastuzumab combinationlinfomalong term effects of herceptinlong term side effects of herceptin treatmentlow immune systemmaintenance herceptinmamariamanufacturer of herceptinmechanism of herceptinmetastasicometastasismetastatic breast cancermonoclonal antibodiesmonoclonal antibody productionmost recent survival rates for her2 positive breast cancermucinosomylotargnavelbineneoadjuvant chemotherapyneoadjuvant her2 positive breast cancerneoplasianeu breast cancerneu her2neu proteinnew drug for her2 positive breast canceromnitargoncogeneoral chemotherapyoseaoveractive immune systemoxaliplatinpaclitaxel and trastuzumabpaclitaxel breast cancerpaclitaxel trastuzumabpalliative chemotherapypancreapancreaspapanicolaoupatologiaperjeta costperjeta herceptinperjeta herceptin taxoterepertuzumabpertuzumab and trastuzumabpertuzumab herceptin docetaxelpertuzumab trastuzumabpertuzumab trastuzumab docetaxelpertuzumab trastuzumab paclitaxelpositive breast cancerpositivity and cancerpr positive breast cancerprostataprotein and breast cancerpulmonarquimioterapiareceptor positive breast cancerrituxanrituximabroche breast cancerroche herceptinroche herceptin pricesalvage chemotherapyseptin cancer drugside effects of herceptin aloneside effects of herceptin and taxolside effects of herceptin chemotherapyside effects of herceptin in breast cancerside effects of herceptin infusionside effects of herceptin injectionside effects of herceptin treatmentsmall her2 positive breast cancerstage 1 her2 breast cancer survival ratesstage 1 her2 positive breast cancerstage 2 breast cancerstage 2 her2 positive breast cancerstage 2 her2 positive breast cancer prognosisstage 3 her2 breast cancer survival ratesstage 3 her2 positive breast cancerstage 3 her2 positive breast cancer prognosisstage 4 breast cancer her2 positive life expectancystage 4 breast cancer survival rate herceptinstage 4 her2 positive breast cancerstage 4 her2 positive breast cancer prognosisstopping herceptin earlysurvival rate stage 2 breast cancer her2 positivet cellstargeted therapy for breast cancertaxol and herceptintaxol and herceptin for breast cancertaxol and herceptin side effectstaxol herceptintaxol herceptin adjuvanttaxol herceptin chemotaxol herceptin side effectstaxoteretaxotere carboplatin herceptintaxotere carboplatin herceptin side effectstaxotere herceptintaxotere herceptin perjetataxotere perjeta herceptintch breast cancertch chemotch chemotherapyterminal cancertrastuzumabtrastuzumab 440 mgtrastuzumab administrationtrastuzumab adverse effectstrastuzumab antibodytrastuzumab approvaltrastuzumab brand nametrastuzumab breast cancertrastuzumab chemical structuretrastuzumab chemotherapytrastuzumab clinical trialstrastuzumab costtrastuzumab definitiontrastuzumab dosetrastuzumab fdatrastuzumab fda approvaltrastuzumab formulationtrastuzumab gastric cancertrastuzumab half lifetrastuzumab heart failuretrastuzumab herceptintrastuzumab indiatrastuzumab indicationstrastuzumab injectiontrastuzumab injection pricetrastuzumab lapatinibtrastuzumab manufacturertrastuzumab mechanismtrastuzumab mechanism of actiontrastuzumab metastatic breast cancertrastuzumab molecular weighttrastuzumab package inserttrastuzumab pitrastuzumab prescribing informationtrastuzumab pricetrastuzumab rochetrastuzumab side effectstrastuzumab structuretrastuzumab therapytrastuzumab toxicitytrastuzumab treatmenttrastuzumab wikitrastuzumab wikipediatrastuzumabetriple positive breast cancertriple positive breast cancer chemotherapytriple positive breast cancer diettriple positive breast cancer prognosistriple positive breast cancer recurrencetriple positive breast cancer recurrence ratetriple positive breast cancer survivaltriple positive breast cancer survival ratestriple positive breast cancer survivorstriple positive breast cancer treatmenttypes of breast cancer her2vinorelbinvinorelbinavinorelbinevumonvysiswhat are the side effects of herceptinwhat causes her2 breast cancerwhat causes her2 overexpressionwhat causes her2 positive breast cancerwhat does herceptin dowhat is chemotherapywhat is docetaxelwhat is docetaxel chemotherapywhat is docetaxel used forwhat is her2what is her2 cancerwhat is her2 negativewhat is her2 negative breast cancerwhat is her2 neuwhat is her2 positivewhat is her2 positive breast cancerwhat is her2 positive breast cancer prognosiswhat is her2 positive cancerwhat is her2 positive metastatic breast cancerwhat is her2 proteinwhat is her2 receptorwhat is her2 testingwhat is herceptinwhat is herceptin and how does it workwhat is herceptin chemotherapywhat is herceptin infusionwhat is herceptin made fromwhat is herceptin therapywhat is herceptin treatmentwhat is herceptin used forwhat is herceptin used to treatwhat is herceptin? (trastuzumab)what is lapatinibwhat is success rate herceptinwhat is the her2 genewhat is trastuzumabwhat is trastuzumab used forwhen was herceptin approvedwho invented herceptinwho makes herceptinxeloda
 What Is Lantus? (insulin glargine)
What Is Bladder Cancer?

You might also like

x1
  • Drugs A To Z

What is Xarelto? (Rivaroxaban)

tumeric2
  • Acne
  • Beauty Tips
  • Cancer A to Z
  • Heatlh A to Z
  • Skin Care
  • Skin Health

The Health Benefits of Turmeric

No Comments

Leave a Reply Cancel Reply

Solve : *
19 − 6 =





Categories

Available For Android App

Subscribe and follow

Popular Posts

  • eylia3

    Avastin, Eylea and Lucentis – What’s the Difference?

    Drugs A To Z / 19, November
  • healthinfi

    How Bone Density influences your Health?

    Addiction Treatment / 13, April
  • healthinfi.png.370ghgfj

    Best Combination Classes In London: Fusion Workouts To Spruce Up Your Exercise Routine

    Health News / 19, June
  • Healthinfi

    Diabetes

    Diabetes / 01, August




Latest Posts

  • amla

    What Amla Can Do For Your Health

    Health Advantages / 08, February
  • apple

    What Is Apple Vinegar’s Health Benefit For Men?

    Health / 03, February
  • well-being

    There are nine indicators that your health is good.

    Health / 02, February
  • egg

    Eating eggs has a Lot of Health Benefits

    Health Advantages / 30, January




Popular Posts

  • x1

    What is Xarelto? (Rivaroxaban)

    Drugs A To Z / 21, November
  • healthinfi.png.386a

    9 Sunscreen Booby Traps To Avoid

    Health News / 30, May
  • health18

    Simple Steps Toward Heart Health

    Health / 10, April
  • Woman with a stomach ache

    Living With Crohn’s Disease

    Health News / 22, May

Available For Android App

  • Top Rated
  • Recent
  • Most Voted

    Latest Posts

    • amla

      What Amla Can Do For Your Health

      Health Advantages / 08, February
    • apple

      What Is Apple Vinegar’s Health Benefit For Men?

      Health / 03, February
    • well-being

      There are nine indicators that your health is good.

      Health / 02, February
    • egg

      Eating eggs has a Lot of Health Benefits

      Health Advantages / 30, January

    About Us

    Healthinfi.Com Provides Valuable Health Information, Tools for managing your health, and support to those who seek information. You can trust that our content is timely and credible.
    HealthInfi

    Important Pages

    • Home
    • About Us
    • Contact Us
    • Advertise
    • Our Policy
    Copyright © Healthinfi 2017-22 |
    All Rights Reserved.